BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AGAH - ECPv5.16.4//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AGAH
X-ORIGINAL-URL:https://dev.agah.eu
X-WR-CALDESC:Veranstaltungen für AGAH
BEGIN:VTIMEZONE
TZID:Europe/Berlin
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20140330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20141026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20140312
DTEND;VALUE=DATE:20140315
DTSTAMP:20260929T022052
CREATED:20190310T123135Z
LAST-MODIFIED:20190607T095253Z
UID:1099-1394582400-1394841599@dev.agah.eu
SUMMARY:23rd AGAH Annual Meeting 2014
DESCRIPTION:Mitigating risks in early medicines development\n\n\n\n	Venue \nKardinal Wendel Haus\nKatholische Akademie in Bayern\nMandlstraße 23\, D-80802 München\nPhone: 0 89 / 38 10 2-0 \n\n\n\n\n	Date \nWednesday\, 12 Mar 2014 (General Assembly)\nThursday\, 13 Mar 2014\nFriday\, 14 Mar 2014 \n\n\n\n\n	Conference office \nCSi Hamburg GmbH\nFalkenried 88\, 20251 Hamburg \nPhone: +49 40 307720 97\nFax: +49 40 846097 60\nE-Mail: info@csihamburg.de \n\n\n\n\n	Fees \n(early bird until January 15\, 2014) \n\n\n\n\nearly bird\nregular\n\n\n\n\nMember\n300 EUR\n350 EUR\n\n\nNon-Member\n380 EUR\n450 EUR\n\n\nJunior Scientists\n150 EUR\n250 EUR\n\n\nDay Ticket (on special request only)\n\n250 EUR\n\n\nConference Dinner\n50 EUR\n50 EUR\n\n\n\n  \n\n\n\n\n	Introduction \nRisk mitigation in early medicines development is the focus of the 2014 Annual Meeting in Munich. Whereas recent meetings mainly addressed aspects of early clinical utility assessment and exploratory development of modern therapies\, there is need for an overall evaluation of risks and in consequence for the advancement of mitigation strategies. \nA broad range of approaches is offered such as the impact of nonclinical findings\, biopharmaceutics\, personalised medicine approaches\, updates on safety/tolerability from a clinical pharmacology perspective\, as well as early investi­­­gation of lack of efficacy. Risk mitigation is increasingly important in early medicines development not only to allow early attrition but also to improve the chances of early drug development. \nIn Plenary Sessions and Parallel Workshops with much room for discussion the AGAH Annual Meeting 2014 will provide a floor for comprehensive exchange on these topics. As the conference is located in Munich the AGAH has taken the initiative to cooperate with BioM (Biotech Cluster Development GmbH\, a nonprofit organisation) in preparing the conference and thereby involve speakers from Munich's biotechnology sector. \nDr. Kerstin Breithaupt-Grögler \nPresident AGAH e.V. \nProf. Dr. Hildegard Sourgens \nPresident Elect AGAH e.V. \n \n\n\n\n\n	Day 1: Wednesday\, 12 Mar 2014 \n  \n\n18:00 – 19:00 \nGet Together / Meet the Board \n\n19:30 \nGeneral Assembly \n\n\n\n\n	Day 2: Thursday\, 13 Mar 2014 \n08:00 \nRegistration \n\n08:45 \nOpening remarks\nK. Breithaupt-Grögler\, Frankfurt \n\n09:00 - 09:30 \nAttrition in clinical development: the earlier\, the better? – an introduction into the conference -\nA. Kovar\, Darmstadt \n\nRisks identified from nonclinical development\nChairs: S. Plassmann\, Muttenz; G. Wensing\, Wuppertal \n\n09:30 \nEarly nonclinical characterisation of drugs in development\nW. Muster\, Basel  \n\n10:00 \nPredictivity of toxicological findings for first-in-man safety\nS. Plassmann\, Muttenz \n\n10:30 \nEarly safety assessment of biologicals\nJ. Sims\, Basel  \n\n11:00  \nBreak \n\nRisks arising from pharmacokinetics / biopharmaceutics\nChairs: B. Schug\, Oberursel; A. Kovar\, Darmstadt \n\n11:30 \nDrug-drug interactions that really matter – focus on transporters\nJ. Rengelshausen\, Aachen \n\n12:00 \nHow to increase “drugability” by use of specific formulations – locally acting\, locally applied\nB. Schug\, Oberursel \n\n12:30 \nHow relevant are drug-food interactions\nH. Blume\, Oberursel \n\n13:00 – 14:15  \nLunch Break \n\nWorkshops \n\n14:15 – 15:45 \n  \n\nIn cooperation with BioM\, München: Personalized medicine – approaches for enhanced drug safety: MetaHeps® – a novel approach to causality assessment in drug-induced liver injury.\nA. Benesic\, München; J. Rengelshausen\, Aachen\nNew guidelines on drug-drug interaction\nU. Fuhr\, Köln; S. Oswald\, Greifswald\nHow to decrease risks in early development of oncological drugs\nH. Oberwittler\, Paris; G. Mikus\, Heidelberg\nPhase I risk mitigation in high risk compounds\nT. van Iersel\, Groningen \n\n\n15:45 – 16:15 \nBreak \n\nRisks related to safety and tolerability\nChairs: T. Sudhop\, Bonn; K. Erb-Zohar\, Hanau \n\n16:15 \nWhen is a subject healthy? – results of two AGAH workshops\nK. Breithaupt-Grögler\, Frankfurt; H. Sourgens\, München \n\n16:45 \nQT assessment in a first-in-man trial – is the earlier really the better?\nJ. Täubel\, London \n\n17:15 \nEthnic differences which may affect safety/tolerability\nK. Diefenbach \n\n17:45 \nEnd of Sessions on Day 1 \n\n19:30 \nConference Dinner \n\n  \n\n\n\n\n	Day 3: Friday\, 14 Mar 2014 \nRisks arising from lack of efficacy\nChairs: J. Rengelshausen\, Aachen; Ingrid Klingmann\, Brüssel\n\n09:00 \nBiomarkers for new anticoagulants – vice and virtue\nD. Kubitza\, Wuppertal \n\n09:30 \nPredictivity of pain models\nK.-H. Konopka\, Leiden \n\n10:00 \nIn cooperation with BioM\, München: Early response monitoring in molecular oncologic treatment regimens by non-invasive imaging techniques?\nC. Cyran\, München \n\n10:30  \nBreak \n\nWorkshops \n\n11:00 – 12:30 \n\nIn cooperation with BioM\, München: Personalized medicine – approaches for enhanced drug safety: Biomarker-based personalized medicine in cardiac arrhythmia\nS. Kääb\, München; J. Rengelshausen\, Aachen \n\nNew guidelines on drug-drug interaction\nU. Fuhr\, Köln; S. Oswald\, Greifswald \n\nHow to decrease risk in early development of oncological drugs\nH. Oberwittler\, Paris; G. Mikus\, Heidelberg \n\nPhase I risk mitigation in high risk compounds\nT. van Iersel\, Groningen \n\nDecreasing risk by investigator training: European training concepts: EMTRAIN\, On-course\, AGAH human pharmacology training course\nI. Klingmann\, Brüssel\n\n\n12:30 – 13:45 \nLunch Break \n\nMitigating risks – pitfalls and perspectives\nChairs: U. Feifel\, Ingelheim; H. Sourgens\, München\n\n13:45 \nFalse positive and false negative biomarkers\nS. Jurcevic\, London \n\n14:15 \nRisk/benefit assessment for new forms of clinical research in the era of molecular biology\nS. Burock\, Brussels \n\n14:45 \nOpen-forum discussion with all speakers and chairs  \n\n15:15 \nClosing remarks \nH. Sourgens\, München \n  \n\n\n\n\n\n	Online Registration \nwww.csioffice.de/secure/conreg_agah2014/registration
URL:https://dev.agah.eu/event/agah-annual-meeting-2014/
LOCATION:Annual Meeting 2014\, München\, Deutschland
CATEGORIES:Jahrestreffen
END:VEVENT
END:VCALENDAR